Skip to main content
Log in

Le sindromi paraneoplastiche endocrine

  • Published:
L’Endocrinologo Aims and scope

Riassunto

Le sindromi paraneoplastiche endocrine conseguono alla produzione da parte di neoplasie di ormoni o altre sostanze in grado di indurre manifestazioni cliniche indipendenti dal tumore primitivo stesso o dalle sue metastasi. Quantunque esistano diverse ipotesi eziopatogenetiche, al momento non ci sono elementi certi che possano spiegare la genesi di tali sindromi. Fra le manifestazioni paraneoplastiche di più frequente riscontro in ambito endocrinologico ci sono l’ipercalcemia, l’ipercorticosurrenalismo, la sindrome da inappropriata secrezione di ADH (SIADH), l’ipoglicemia e l’acromegalia paraneoplastica. La terapia, ove possibile, prevede la rimozione del tumore causale. Peraltro, trattandosi in genere di tumori maligni, la prognosi è infausta e l’approccio terapeutico è indirizzato alla normalizzazione dei parametri biochimici fuori norma, con il fine di migliorare la qualità di vita dei pazienti.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. Agarwala SS. Paraneoplastic endocrine syndromes. Med Clin North Am 80: 173, 1996.

    Article  CAS  PubMed  Google Scholar 

  2. Baylin SB, Mendelsohn G. Ectopic (inappropriate) hormone production by tumors: mechanisms involved and the biological and clinical implication. Endocr Rev 1: 45, 1980.

    Article  CAS  PubMed  Google Scholar 

  3. De Lellis R, Xia L. Paraneoplastic endocrine syndromes: a review. Endocr Path 14: 303, 2003.

    Article  Google Scholar 

  4. Klemperer P. Parathyroid hyperplasia and bone destruction in generalized carcinomatosis. Surg Gynecol Obstet 36: 11, 1923.

    Google Scholar 

  5. Case Records of the Massachusetts General Hospital (case 27461). N Engl J Med 225: 789, 1941.

    Google Scholar 

  6. Davies M, Hayes ME, Yin JA, Berry JL, Mawer EB. Abnormal synthesis of 1, 25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 78: 1202, 1994.

    CAS  PubMed  Google Scholar 

  7. Mariotti S, Sammartano L. Paraneoplastic endocrine syndromes. In: Pinchera A, Bertagna XY, Fischer JA, Groop L, Schoemaker J, Serio M, Wass JA, Braverman LE (Eds.) Endocrinology and Metabolism. McGraw-Hill, London, 2001, p 737.

    Google Scholar 

  8. Strewler GJ. Humoral manifestations of malignancy. In: Larsen PR, Fronenber HM, Melmed S, Polonsky KS (Eds.) Williams Text-book of Endocrinology, 4th ed. WB Saunders, Philadelphia, 2001, p. 2559.

    Google Scholar 

  9. Vassilopoulou-Sellin R, Newman N, Taylor SH, Guinee VR. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71: 1309, 1993.

    Article  CAS  PubMed  Google Scholar 

  10. Mundy G, Guise TA. Hypercalcemia of malignancy. Am J Med 103: 134, 1997.

    Article  CAS  PubMed  Google Scholar 

  11. Philbrick WM. Parathyroid hormone related protein: gene structure, biosynthesis, metabolism and regulation. In: Bilezekian J (Ed.) The parathyroid, basic and clinical concepts, 2nd ed. Academic Press, San Diego, 2000, p. 31.

    Google Scholar 

  12. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s syndrome due to ectopic corticotrpin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 90: 4955, 2005.

    Article  CAS  PubMed  Google Scholar 

  13. Grossrubatscher E, Loli P. La sindrome di Cushing da secrezione ectopica di ACTH. L’Endocrinologo 7: 11–22, 2006.

    Google Scholar 

  14. Newell-Price J, Trainer P, Besser M, Grossaman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19: 647, 1998.

    CAS  PubMed  Google Scholar 

  15. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Ktaz DA, Cutler GB Jr, Loriaux DL. Petrosal sinus sampling with and without corticotrophinreleasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 325: 896, 1991.

    Article  Google Scholar 

  16. Sorensen JB, Anderson MD, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant diseases. J Internal Med 238: 97, 1995.

    Article  CAS  PubMed  Google Scholar 

  17. Gainer H, Wray S. Oxyotcin and vasopressin: from genes to peptide. Ann NY Acad Scie 652: 14, 1992.

    Article  CAS  Google Scholar 

  18. Sausville E, Carney D, Batey J. The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem 260: 10235, 1985.

    Google Scholar 

  19. Pequeux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R, Greenen V, Legros JJ. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signalling. Cancer Res 62: 4623, 2002.

    CAS  PubMed  Google Scholar 

  20. Daughday WH. Hypoglycemia in patients with non-islet cell tumors. Endocrinol Metab Clin North Am 18: 91, 1989.

    Google Scholar 

  21. Hizuka N, Fukada I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J 45 (Suppl): S61, 1998.

    Article  CAS  PubMed  Google Scholar 

  22. Faglia G, Arosio M, Bazzoni N. Ectopic acromegaly. Endocrinol Metab Clin North Amer 21: 575, 1992.

    CAS  Google Scholar 

  23. Braunstein GD, Vaitukaitis JL, Carbonew PP, Ross GT. Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Int Med 78: 39, 1973.

    Article  CAS  PubMed  Google Scholar 

  24. Sheth NA, Suraiya JN, Sheth AR, Ranadive KJ, Jussawalla DJ. Ectopic production of human placental lactogen by human breast tumors. Cancer 39: 1693, 1977.

    Article  CAS  PubMed  Google Scholar 

  25. Roos BA, Lindall AW, Baylin SB, O’Neil JA, Frelinger AL, Birnbaum RS, Lambert PW. Plasma immunoreactive calcitonin in lung cancer. J Clin Endocrinol Metab 50: 659, 1980.

    Article  CAS  PubMed  Google Scholar 

  26. Samaan NA, Castillo S, Schultz PN, Khalil KG, Johnston DA. Serum calcitonin after pentagastrin stimulation in patients with bronchogenic and breast cancer compared to that in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 51: 237, 1980.

    Article  CAS  PubMed  Google Scholar 

  27. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 59: 1442, 1981.

    Article  Google Scholar 

  28. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA 98: 6500, 2001.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Hirshberg B, Conn PM, Uwaifo GI, Blauer KL, Clark BD, Nieman LK. Ectopic luteinizing hormone secretion and anovulation. N Engl J Med 348: 312, 2003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefano Mariotti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mariotti, S., Pinna, G. Le sindromi paraneoplastiche endocrine. L’Endocrinologo 7, 118–127 (2006). https://doi.org/10.1007/BF03344545

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344545

Navigation